Stocks•12 November 2026•
1 min read
Nektar Therapeutics Reports $952.9 Million Cash Position in Q3 2026 Results
Key Facts
1Nektar Therapeutics reported cash and investments of $952.9 million as of September 30, 2026.
2Zefiro Methane reported revenue of $12.1 million for its fiscal first quarter, a 31% sequential increase.
Nektar Therapeutics reported cash and investments of $952.9 million as of September 30, 2026, according to a statement carried by PR Newswire. The company recorded a net loss of $55.7 million, or $1.63 per share, for the third quarter of 2026.
NKTR closed at $38.44 on November 11, 2026, ahead of these periodic financial updates. Separately, Zefiro Methane reported revenue of $12.1 million for its fiscal first quarter ending September 30, 2026, representing a 31% sequential increase.